Ongoing Trials – status update

PORTEC-4a

Trial setting: Stage I-II endometrial cancer - high-intermediate risk

Study Design: Randomised trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy

Sponsor(s): LUMC; funding: Dutch Cancer Society

Planned No. of patients: 500

Current accrual: 80

Other important information: ANZGOG and NCRI UK planning to participate, awaiting grant application, validation of pathology labs

Inclusion criteria: FIGO 2009 – high intermediate risk

- Stage IA (with invasion), any age with grade 3
- Stage IB, grade 1-2 and age > 60
- Stage IB, grade 1-2 and LVSI+
- Stage IB, grade 3 without LVSI
- Stage II (microscopic), grade 1

Ongoing Trials – status update

PORTEC-4a





Ongoing Trials – status update

PORTEC-4a

Pilot phase (n=50) endpoints:

- Logistics of molecular analysis (< 2 wks)
- Patient acceptance
- Completed: 50 pts

PORTEC-4a study endpoints (n=500):

- Vaginal control and RFS
- Pelvic and distant recurrence and OS
- Quality of life and freedom from symptoms
- Costs and use of health care resources
- Current total: 80

➢ Satellite : Nov 3, 10:45-11:00 h, Seminarraum Room